GlassScriptPhysician profile
Leah Mcgeary
NPI 1649715194
$2,040.26
in general payments reported to CMS, 2019-2025
20 companies · $2,040 in 2025
The $2,040 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,040.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $310.33 | 2025 | Fanapt |
| Abbvie INC. | $257.09 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.01 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $158.75 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $153.92 | 2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $153.14 | 2025 | Rexulti |
| Pfizer INC. | $112.26 | 2025 | |
| Glaxosmithkline, LLC. | $105.47 | 2025 | Trelegy Ellipta |
| Alkermes, INC. | $93.60 | 2025 | Aristada, Vivitrol, Lybalvi |
| Corcept Therapeutics | $84.89 | 2025 | Korlym |
| Lundbeck LLC | $78.95 | 2025 | Rexulti |
| Novo Nordisk INC | $75.58 | 2025 | Wegovy |
| Amgen INC. | $72.59 | 2025 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $52.20 | 2025 | Eohilia, Trintellix |
| Neurocrine Biosciences, INC. | $40.30 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $38.97 | 2025 | Zenpep |
| Exact Sciences Corporation | $23.66 | 2025 | The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $23.62 | 2025 | Auvelity |
| Dexcom, INC. | $17.04 | 2025 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $13.89 | 2025 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Mcgeary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.